Ski, Norway

Torsten Knüttel

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Torsten Knüttel

Introduction

Torsten Knüttel is a notable inventor based in Ski, Norway. He has made significant contributions to the field of medical diagnostics, particularly in the quantification of NT-proBNP. His innovative approach has led to the development of a highly sensitive assay that has the potential to improve clinical outcomes.

Latest Patents

Torsten Knüttel holds a patent for a "Highly sensitive particle enhanced assay for the quantification of NT-proBNP." This patent describes a method for determining NT-proBNP in biological samples using at least one antibody that recognizes an epitope of NT-proBNP in both glycosylated and non-glycosylated forms. The antibody is preferably an isolated polyclonal antibody or a mixture of monoclonal antibodies coated onto a particle. The coating ratio is ideally between 6-60%, forming a layer or multiple layers of antibodies on the particle. This assay can be realized in the form of a nephelometric or turbidimetric assay and is applicable to a wide range of automated clinical analyzers.

Career Highlights

Torsten Knüttel is associated with Gentian AS, a company that focuses on developing innovative diagnostic solutions. His work at Gentian AS has been instrumental in advancing the field of clinical diagnostics, particularly in the area of heart failure biomarkers.

Collaborations

Some of his notable coworkers include Ingvild Gudim and Berit Løseth. Their collaborative efforts contribute to the innovative environment at Gentian AS, fostering advancements in medical technology.

Conclusion

Torsten Knüttel's contributions to the field of medical diagnostics through his innovative patent demonstrate his commitment to improving healthcare solutions. His work continues to influence the development of sensitive assays that can enhance patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…